Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
US STATE DEPARTMENT: US WON'T HOLD A 2ND ROUND OF TALKS BETWEEN THE LEBANESE AND ISRAELI AMBASSADORS THIS THURSDAY
2026-04-21
US STATE DEPARTMENT: US WON'T HOLD A 2ND ROUND OF TALKS BETWEEN THE LEBANESE AND ISRAELI AMBASSADORS THIS THURSDAY
Back
Other News
2026-04-20
SOURCES: VANCE EXPECTED TO DEPART DC ON TUESDAY FOR PAKISTAN - CNN
SOURCES: VANCE EXPECTED TO DEPART DC ON TUESDAY FOR PAKISTAN - CNN
2026-04-20
Novo Nordisk (NVO.N): etovopivat met both co-primary endpoints in the Phase III HIBISCUS trial for sickle cell disease, significantly reducing vascular occlusive crisis events and improving hemoglobin response in patients with sickle cell disease. In
Novo Nordisk (NVO.N): etovopivat met both co-primary endpoints in the Phase III HIBISCUS trial for sickle cell disease, significantly reducing vascular occlusive crisis events and improving hemoglobin response in patients with sickle cell disease. In the Phase III trial, etovopivat reduced vascular occlusive crisis events by 27%. The company plans to submit its first regulatory application for etovopivat in the second half of 2026.
Chat with us
, powered by
LiveChat